Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

AstraZeneca plc. (3/14/17). "Press Release: Lynparza Phase III SOLO-2 Data Demonstrate Progression-free Survival Benefit in BRCA-mutated Ovarian Cancer as Maintenance Therapy".

Organisations Organisation AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
  Organisation 2 European Network for Gynaecological Oncological Trial groups (ENGOT)
  Group European Society of Gynaecological Oncology (ESGO)
Products Product Lynparza®
  Product 2 clinical research
Person Person Bohen, Sean (AstraZeneca 201509– EVP Global Medicines Developent + CMO before Genentech + Stanford Univ)
     


   
Record changed: 2023-06-05

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for AstraZeneca (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px




» top